Les meilleurs doctors traitant la maladie suivante : Immunotherapy - TOP -11 des médecins

Le Dr Rahib Hasanov, spécialiste, intègre l'immunothérapie moderne et les thérapies ciblées dans des traitements oncologiques personnalisés, fort d'une expérience internationale au Houston Methodist Hospital.

• A achevé sa spécialisation en oncologie médicale à la faculté de médecine de l'université de Marmara
• A participé à de nombreux congrès nationaux et internationaux sur les progrès de l'oncologie
• Se spécialise dans le cancer du poumon, y compris les traitements par immunothérapie
• Soigner des patients originaires d'Europe, des États-Unis et des pays du Moyen-Orient

Le Dr Pastrana est un chirurgien oncologue certifié, expert en immunothérapie à l'Hôpital Galenia.

• Certifié par le Conacem – le principal organisme d'accréditation médicale du Mexique
• Membre actif de la SMEO (Société Mexicaine d'Oncologie)
• Professeur universitaire à l'Universidad Anahuac depuis 2020
• Titulaire d'un diplôme de l'Universidad Autónoma de México

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.